Hisamitsu Pharmaceutical Co., Inc.

OTCPK:HTSU.F Stock Report

Market Cap: US$1.9b

Hisamitsu Pharmaceutical Management

Management criteria checks 1/4

Hisamitsu Pharmaceutical's CEO is Kazue Nakatomi, appointed in May 2015, has a tenure of 9.17 years. directly owns 0.33% of the company’s shares, worth $6.37M. The average tenure of the management team and the board of directors is 1 years and 10.2 years respectively.

Key information

Kazue Nakatomi

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.2yrs
CEO ownership0.3%
Management average tenureless than a year
Board average tenure10.2yrs

Recent management updates

Recent updates


CEO

Kazue Nakatomi (52 yo)

9.2yrs

Tenure

Mr. Kazuhide Nakatomi, also known as Kazue, serves as Chief Executive Officer since May 2019, President since May 2015 & Director since May 2007 at Hisamitsu Pharmaceutical Co. Inc. and served as its Chief...


Leadership Team

NamePositionTenureCompensationOwnership
Kazuhide Nakatomi
President9.2yrsno data0.33%
$ 6.4m
Naruhito Higo
Executive VPless than a yearno datano data
Nobuo Tsutsumi
Exe Officer of Legal Affairs10.2yrsno data0.0068%
$ 130.1k
Kosuke Sugiyama
Executive MD of Human Resourcesless than a yearno data0.018%
$ 338.0k
Tetsuo Akiyama
Senior Managing Executive Officerless than a yearno datano data
Kyu Saito
MD, Executive Officerno datano data0.0095%
$ 182.0k
Shinichi Murayama
Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Directorno datano data0.0082%
$ 156.0k
Mitsutoshi Tsuruta
Senior Executive Officer & GM of Pharmaceutical Business Divisionno datano datano data
Masaya Okuno
Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Divisionno datano datano data
Koji Takiyama
Executive Officer3.2yrsno data0.0041%
$ 78.0k
Katsuhiko Akiyama
Senior Executive Officer & GM of MN Business Promotion Office1.5yrsno datano data
Tomoya Suzuki
Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Divisionless than a yearno datano data

1.0yrs

Average Tenure

58.5yo

Average Age

Experienced Management: HTSU.F's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kazuhide Nakatomi
President17.2yrsno data0.33%
$ 6.4m
Nobuo Tsutsumi
Exe Officer of Legal Affairs10.2yrsno data0.0068%
$ 130.1k
Kosuke Sugiyama
Executive MD of Human Resources25.2yrsno data0.018%
$ 338.0k
Kyu Saito
MD, Executive Officer11.2yrsno data0.0095%
$ 182.0k
Shinichi Murayama
Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director10.2yrsno data0.0082%
$ 156.0k
Koji Takiyama
Executive Officer3.2yrsno data0.0041%
$ 78.0k
Munehiko Hirano
Standing Corporate Auditor18.2yrsno data0.0027%
$ 52.1k
Tetsugo Matsuo
Part-time Outside Independent Director4.2yrsno data0.0014%
$ 25.9k
Yuichiro Anzai
Part-time Outside Independent Director4.2yrsno datano data
Kentaro Watanabe
Part Time Outside Corporate Auditor1.2yrsno datano data
Tamako Watanabe
Part Time Outside Independent Director1.2yrsno datano data

10.2yrs

Average Tenure

57yo

Average Age

Experienced Board: HTSU.F's board of directors are seasoned and experienced ( 10.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/20 14:49
End of Day Share Price 2024/04/23 00:00
Earnings2024/05/31
Annual Earnings2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Toshiro YoshinagaAizawa Securities Co. Ltd.
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.